In: Kardiovaskuläre Medizin, 2010, vol. 13, no. 2, p. 68-69
|
In: Trials, 2014, vol. 15, no. 1, p. 9
Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...
|
In: Minimally Invasive Surgery, 2011, p. -
The development of ventricular assist devices has broadened the means with which one can treat acute heart failure. Percutaneous ventricular assist devices (pVAD) have risen from recent technological advances. They are smaller, easier, and faster to implant, all important qualities in the setting of acute heart failure. The present paper briefly describes the functioning and assets of the most...
|
In: European Heart Journal, 2008, vol. 29, no. 6, p. 718-725
|
In: Value in Health, 2019, vol. 22, no. 12, p. 1355–1361
Elderly patients receive bare metal stents instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT). The SENIOR trial compared outcomes between these 2 types of stents combined with a short duration of DAPT. A significant decrease in the number of patients with at least 1 major adverse cardiac and cerebrovascular event (MACCE) was noted in the DES...
|
In: Cardiovascular Revascularization Medicine, 2019, vol. 20, no. 7, p. 577–582
Background: The advent of bioresorbable vascular scaffolds (BVS) was considered as a potential improvement in percutaneous coronary intervention (PCI) after the groundbreaking development of drug eluting stents (DES). However, the clinical performance, long-term safety and efficacy of BVS in complex coronary lesions remain uncertain. COMPARE ABSORB, a multicenter, single blind, prospective ...
|
In: European Heart Journal, 2017, p. -
To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions.Methods and Results: A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model...
|
In: Open Heart, 2016, vol. 3, no. 1, p. e000373
Background Interventional cardiologists may be immune to stress, allowing them to perform complex percutaneous interventions under pressure.Objectives To assess heart rate (HR) variations as a surrogate marker of stress of interventional cardiologists during percutaneous cardiac procedures and in every-day life.Design This is a single-centre...
|
In: Journal of Interventional Cardiology, 2010, vol. 23, no. 2, p. 176-178
|
In: Swiss Medical Weekly, 2012, vol. 142, p. w13661
|